OncoMatch

OncoMatch/Clinical Trials/NCT06890598

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Is NCT06890598 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Olomorasib and Pembrolizumab for carcinoma, non-small-cell lung.

Phase 3RecruitingEli Lilly and CompanyNCT06890598Data as of May 2026

Treatment: Olomorasib · Pembrolizumab · Durvalumab — The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Required: KRAS G12C mutation

Must have disease with evidence of KRAS G12C mutation.

Required: PD-L1 (CD274) expression (known)

Must have known programmed death-ligand 1 (PD-L1) expression

Required: EGFR alteration

Have known changes in the EGFR or ALK genes.

Required: ALK alteration

Have known changes in the EGFR or ALK genes.

Disease stage

Required: Stage II, IIIA, IIIB (N2), III

Part A: Clinical Stage II-IIIB (N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible. Pathologic Stage II-IIIB (N2) NSCLC treated with initial upfront resection. Part B: Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy.

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Clearview Cancer Institute · Huntsville, Alabama
  • Infirmary Cancer Care · Mobile, Alabama
  • The University of Arizona Cancer Center - North Campus · Tucson, Arizona
  • Highlands Oncology Group · Springdale, Arkansas
  • UCLA Hematology/Oncology - Santa Monica · Los Angeles, California

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify